PDCD1 and gastric adenocarcinoma: In a randomized, phase III trial, compared to chemotherapy alone, the PD-1 inhibitor Nivolumab combined with chemotherapy showed superior overall survival (OS) and progression-free survival (PFS) in previously untreated patients with advanced gastric adenocarcinoma (37).